摘要
目的探讨重组人血管内皮抑制素在中晚期非小细胞肺癌治疗中的临床疗效。方法将我院收治的87例中晚期非小细胞肺癌患者,按照收治时间段分为观察组(n=51)和对照组(n=36)。对照组给予PC化疗方案,观察组给予重组人血管内皮抑制素+PC化疗,观察两组患者的临床疗效及预后。结果观察组临床控制率为94.1%(48/51),临床有效率为76.5%(39/51),严重不良反应发生率为17.6%(9/51),肺癌患者生命质量中文版量表(QLQ-LC43)评分为(79.67±1.94)分,1年生存率为96.1%(49/51);对照组临床控制率为72.2%(26/36),有效率为50.0%(18/36),严重不良反应发生率为30.6%(11/36),QLQ-LC43生活质量评分为(67.09±1.54)分,1年生存率为83.3%(30/36)。两组间临床疗效和预后差异均有统计学意义(P<0.05)。结论重组人血管内皮抑制素能显著提高化疗效果,对于提高患者生存率及生活质量具有积极意义。
Objective To explore the clinical efficacy of recombinant human endostatin in the treatment of advanced non-small cell lung cancer. Methods According to the hospitalized time,87 patients with advanced non-small cell lung cancer were divided into ob- servation group and control group in our hospital. The patients were given PC chemotherapy in control group and recombinant human en- dostatin ＋ PC chemotherapy in observation group. The clinical efficacy and prognosis of patients were observed. Results The clinical control rate was 94.1% （48/51 ） in observation group and 72.2% （26/36） in control group （ P 〈 0.05 ）, the clinical response rate was 76.5 % （ 39/51 ） in observation group and 50.0% （18/36） in control group （ P 〈 0.05 ） , the incidence of serious adverse reactions was 17.6% （9/51） in observation group and 30.6% （ 11/36 ） in control group（ P 〈 0.05 ）, QLQ-LCA3 score was 79.67± 1.94 in observation group and 67.09± 1.54 in control group （ P 〈 0.05 ）, and the 1-year survival rate was 96.1% （49/51 ） in observation group and 83.3% （30/36） in control group（P 〈0. 05）. Conclusion Recombinant human endostatin can significantly improve the efficacy of chemotherapy, and it has a positive significance to improve the survival rate and quality of life.
出处
《山西医科大学学报》
CAS
2013年第9期724-726,共3页
Journal of Shanxi Medical University
关键词
重组人血管内皮抑制素
非小细胞肺癌
临床疗效
recombinant human endostatin
non-small cell lung cancer
clinical efficacy
